The typical Epitalon researcher is a longevity-curious adult in their late 30s or older who already tracks fasting glucose, HRV, and sleep. They have usually cycled NAD+ or looked at it, read the Khavinson papers in translation, and want a second lever that does not collide with the sirtuin pathway. They want something pulsed, not chronic.
Epitalon is a short synthetic peptide (Ala-Glu-Asp-Gly, four amino acids) developed at the St. Petersburg Institute of Bioregulation and Gerontology under Professor Vladimir Khavinson. It is the synthetic analog of Epithalamin, a pineal gland extract studied in Soviet labs since the 1970s. Three decades of Russian publications anchor the file. Most are small-N, several have methodological issues by current US trial standards, but the body of work is real.
What Epitalon actually is
Strictly speaking, Epitalon is a tetrapeptide. The sequence is alanine, glutamic acid, aspartic acid, glycine. Molecular weight is small (about 390 Daltons), the half-life is short (minutes in circulation), and the active mechanism is thought to be pineal axis modulation plus telomerase signaling in somatic cells. The molecule was not engineered to replace a hormone. It was engineered to send a regulatory pulse.
The mechanism story (in plain English)
Three threads run through the published research. First, in cell-culture work, Epitalon was reported to upregulate telomerase activity in human somatic cells, which would lengthen chromosome end caps that shorten with each cell division. Second, in animal work, melatonin amplitude shifted toward a more youthful nighttime peak. Third, in mixed clinical work, aging biomarkers like cortisol rhythm and pulse variability shifted modestly toward younger-cohort norms. None of these threads is a settled question. All are why the research interest persists.
Why the cycle is days, not weeks
Khavinson's original protocols ran Epitalon as a 10-day course, once or twice per year, at microgram doses. That cadence is the opposite of what most US peptide users expect. The reasoning is bioregulator logic: send a regulatory pulse to the pineal axis, then let the axis run for months. Continuous daily dosing was never part of the Russian protocol design, and the small body of long-term continuous-dose data does not support it.
Quick reference table
| Spec | Value | Note |
|---|---|---|
| Sequence | Ala-Glu-Asp-Gly | 4 amino acids, ~390 Da |
| Standard course | 10 to 20 days | 1 to 2 courses per year |
| Research dose range | 5 to 10 mg total per course (subq) | Some protocols split across the 10 days |
| Half-life | ~30 minutes (estimated) | Pulse mechanism, not steady-state |
| Storage | 36 to 46 F after reconstitution | Use within 30 days post-reconstitution |
| Mechanism focus | Pineal axis, telomerase, melatonin rhythm | Per Khavinson group publications |
What longevity researchers track on Epitalon
Subjective sleep depth (especially deep-sleep minutes on a wearable) is the marker most researchers report shifting first. HRV trending up over the course of a 10-day pulse is the second. Most other markers (fasting glucose, blood pressure, AM cortisol) take longer than a single pulse to move, and are usually tracked across two or three pulses over a year. The anti-aging telomere length question requires lab work most researchers do not have access to and is best framed as the long-term question.
How Epitalon fits with NAD+
NAD+ runs the sirtuin pathway and mitochondrial energy axis. Epitalon runs the pineal axis and telomerase signaling. Different rooms, same building. The two are commonly stacked non-overlapping: a longer NAD+ protocol once or twice a year (typically 5 to 10 day intensives), and an Epitalon pulse run in a separate window. The two are not redundant and there is no published reason they would interfere.
Compared to Pinealon
Pinealon is the 3-amino brain-targeted bioregulator from the same Khavinson research program. It crosses the blood-brain barrier more readily and is framed around cortical neurons rather than the pineal axis itself. Researchers running both typically use Epitalon for the pineal/melatonin angle and Pinealon for the cognitive angle. Both run in 10-day pulses.
External citations and source authority
The bulk of the Epitalon literature was published by the Khavinson group at the St. Petersburg Institute of Bioregulation and Gerontology and indexed in PubMed. The Wickramasinghe and Anisimov groups have replicated subsets of the work. Western reviews in Aging Cell and Biogerontology have covered the bioregulator framework. Most of the clinical data sits in Russian-language journals and is summarized in English reviews rather than reproduced directly. This is the standard reading shape for the file.
The compliance frame
Epitalon is not FDA-approved. It is not a drug in the regulatory sense. It is sold in the US as research-use-only material for in-vitro and laboratory study. Aion ships Epitalon with research-grade labeling and a third-party COA. Any decision about your own use is a conversation for a qualified clinician familiar with peptide research.
Bottom line
Epitalon is a 4-amino pulse-dosed pineal peptide with a 30-year Russian research record and growing Western replication interest. Its frame is not "take this every day." Its frame is "send the pineal axis a regulatory pulse once or twice a year." That cadence, more than any specific dose, is the part most newcomers miss.